Prevalence and prognosis of patients with MASLD‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study

Author:

Sultanik Philippe1,Lherault Guillaume1,Bouzbib Charlotte1,Ratziu Vlad123,Pais Raluca123,Mouri Sarah1,Thabut Dominique123ORCID,Rudler Marika123

Affiliation:

1. AP‐HP, Sorbonne Université, Liver Intensive Care Unit Hepatogastroenterology Department, Pitié‐Salpêtrière Hospital Paris France

2. INSERM UMR_S 938, Centre de Recherche Saint‐Antoine, Maladies métaboliques, Biliaires et Fibro‐Inflammatoire du Foie Institute of Cardiometabolism and Nutrition (ICAN) Paris France

3. Hôpital de la Pitié‐Salpêtrière, Service d'hépato‐Gastro‐entérologie, unité de Soins Intensifs d'hépatologie Sorbonne Université, AP‐HP. Sorbonne Université Paris France

Abstract

SummaryBackground and AimsThe prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related cirrhosis has been increasing these last decades. There are no data regarding the prevalence of MASLD‐related cirrhosis in intensive care unit (ICU).MethodsProspective single‐centre study in a cohort of patients hospitalized in the ICU of Hepatology La Pitié‐Salpêtrière Hospital between January 2019 and September 2021. We analysed three groups of patients: MASLD‐cirrhosis (alcohol ≤210 g for men and 140 g weekly for women), ALD (alcohol‐related liver disease, alcohol>140 g weekly for women or >210 g for men)‐cirrhosis alone and MetALD (metabolic and alcohol‐related liver disease)‐cirrhosis. Endpoints were 1‐year transplant‐free survival (TFS), further acute decompensation (AD) and re‐admission.ResultsA total of 410 patients were hospitalized, and 315 analysed: 39 in MASLD, 160 in ALD and 116 in MetALD groups. The global prevalence was 10% for MASLD, 41% ALD and 29.7% for MetALD. Patients in the MASLD group were significantly older (65 vs. 57 and 59 years, p < 0.001), and had lower Child‐Pugh (8 vs. 11 vs. 10, p < 0.001) and MELD score (17 vs. 22 vs. 21, p < 0.001). The 1‐year TFS was not different between groups (53% vs. 54% vs. 54%, p = 0.96). Cardiovascular mortality was <5% in all groups. The 1‐year probability of developing hepatic encephalopathy was significantly higher in the MASLD group (73% vs. 27% and 21%, p < 0.001). There was no difference regarding the development of other complications between groups.ConclusionMASLD or MetALD was responsible for 1/3 of the causes of cirrhosis in the ICU. MASLD‐related cirrhosis is as severe as ALD‐related cirrhosis. Liver transplantation should be rapidly discussed.

Publisher

Wiley

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Editorial: Quantity is important!;Alimentary Pharmacology & Therapeutics;2024-08-12

2. Editorial: Quantity is important! Authors' reply;Alimentary Pharmacology & Therapeutics;2024-08-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3